Therefore, the hypothesis is that a rise in IGFBP3 levels in NAFLD patients with the “GT+TT” genotype may result in a reduction in the bioavailability of IGF1 as a hepatoprotective factor at tissue levels. This evidence concerns the gene IGFBP3 and metabolic dysfunction-associated steatotic liver disease.